Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Italian Stock Exchange  >  Recordati    REC   IT0003828271

RECORDATI (REC)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Italian Stock Exchange
12/04/2017 12/05/2017 12/06/2017 12/07/2017 12/08/2017 Date
37.89(c) 38.73(c) 38.31(c) 38.05(c) 38.68(c) Last
262 515 644 340 368 619 276 711 368 474 Volume
+0.69% +2.22% -1.08% -0.68% +1.66% Change
More quotes
Financials (€)
Sales 2017 1 296 M
EBIT 2017 408 M
Net income 2017 290 M
Debt 2017 277 M
Yield 2017 2,14%
Sales 2018 1 415 M
EBIT 2018 444 M
Net income 2018 313 M
Debt 2018 161 M
Yield 2018 2,32%
P/E ratio 2017 27,66
P/E ratio 2018 25,14
EV / Sales2017 6,45x
EV / Sales2018 5,83x
Capitalization 8 089 M
More Financials
Company
Recordati SpA engages in the research, development, manufacturing, and marketing of pharmaceuticals.It operates through two segments: Pharmaceutical and Rare Diseases.The Pharmaceutical segment offers prescription and over-the-counter products as well as chemical syntheses, intermediates, and... 
Sector
Pharmaceuticals
Calendar
02/08Earnings Release
More about the company
Surperformance© ratings of Recordati
Trading Rating : Investor Rating :
More Ratings
Latest news on RECORDATI
11/20 RECORDATI : ex-dividend day for interim dividend
10/26 RECORDATI : Excellent results in the first nine months 2017. continued growth in..
10/26 RECORDATI : Very good results in the first nine months 2017. continued growth in..
07/27 RECORDATI : Very good results again in the first half 2017. continued growth in ..
07/27 RECORDATI : Very good results in the first half 2017. continued growth in sales ..
07/19 RECORDATI : The european commission approves reagila® (cariprazine) for the trea..
07/07 RECORDATI : Rare Diseases Introduces New PANHEMATIN® (Hemin for Injection) Dosag..
07/03 RECORDATI : Acquisition of rights to astrazeneca's metoprolol based treatments i..
07/03 ASTRAZENECA : Completes agreement with recordati for seloken in europe
06/16 RECORDATI : Licenses an innovative treatment for neurotrophic keratitis
More news
Sector news : Pharmaceuticals - NEC
09:21a European shares inch up near four-week highs helped by banks
07:45aDJROCHE : Reports Positive Results From IMmotion151 Kidney Cancer Trial
07:32a ROCHE : Tecentriq cocktail slows kidney cancer progression
07:08a Monsanto offers cash to U.S. farmers who use controversial chemical
07:03a Merck raises stakes in lung cancer as rivals close in
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on RECORDATI 
RECORDATI SPA - 2016
A medium term support level to take advantage of
BUY
RECORDATI - 2014
Jump above 2-year old trend line
BUY
More Strategies
News from SeekingAlpha
10/26 Recordati Industria Chimica e Farmaceutica reports 9M results
07/27 Recordati Industria Chimica e Farmaceutica reports 1H results
07/10 Strong Small Cap Performance Drives Second-Quarter Gains
05/22 WALL STREET BREAKFAST : Major Shakeup At Ford?
05/22 AstraZeneca sells Seloken for $300M
Chart RECORDATI
Duration : Period :
Recordati Technical Analysis Chart | REC | IT0003828271 | 4-Traders
Technical analysis trends RECORDATI
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Average target price 37,8 €
Spread / Average Target -2,4%
EPS Revisions
Managers
NameTitle
Andrea Recordati Vice Chairman & Chief Executive Officer
Alberto Recordati Chairman
Fritz Squindo Chief Financial Officer, Executive Director & MD
Mario Garraffo Independent Non-Executive Director
Marco Vitale Lead Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
RECORDATI42.31%9 520
JOHNSON & JOHNSON21.23%377 698
NOVARTIS11.34%218 728
PFIZER9.48%213 036
ROCHE HOLDING LTD.6.19%208 877
MERCK AND COMPANY-7.68%151 559